---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006543"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:36:24.283568+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NextCure posts Q1 net loss of $17.1M; cash $96M; NC410 data at ASCO June 1

## Summary
- Cash $96.0M as of March 31, 2024, down $12.3M from Q4 2023; expected to fund operations into H2 2026.
- Net loss of $17.1M for Q1 2024 vs $16.1M in Q1 2023; R&D $11.4M, G&A $4.4M, restructuring costs $2.5M.
- Phase 1b NC410 combo with pembrolizumab data at ASCO June 1, including additional 20 CRC patients.
- LNCB74 (B7-H4 ADC) advancing; IND submission planned by year-end with GLP tox studies initiated.

## SEC filing metadata
- accession: 0001558370-24-006543
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/0001558370-24-006543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/nxtc-20240502x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006543
- JSON: https://secwatch.observer/filing/0001558370-24-006543.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006543.txt

## Key facts
- Earnings Releases
  NextCure, Inc. reported first quarter 2024 results: net income Net loss was $17.1 million.
  - Period: first quarter 2024
  - Net income: Net loss was $17.1 million
  - Result: reported results
  source text: NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/0001558370-24-006543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.